Article

A nomogram to predict the high-risk RS in HR+/HER2-breast cancer patients older than 50 years of age

2020-10-20

Abstract excerpt

<title>Abstract</title> <p><bold>Background: </bold>The 21-gene recurrence score (RS) testing can predict the prognosis for luminal breast cancer patients. Meanwhile, patients >50 years with RS >25 have improved survival with adjuvant chemotherapy. The current study aimed to develop a nomogram with routine parameters to predict RS.<bold>Methods</bold>: We included patients diagnosed with hormone receptor (HR)-pos...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a647145f-8c89-58bb-a64c-f861696b1ad1
DOI: 10.21203/rs.3.rs-93486/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A nomogram to predict the high-risk RS in HR+/HER2-breast cancer patients older than 50 years of ageDOI 10.21203/rs.3.rs-93486/v1Read

Impact of Different Modules of 21-Gene Assay in Early Breast Cancer PatientsSemantic proximity Read

A 95-gene Signature Stratifies Recurrence Risk of Invasive Disease in ER-positive, HER2-negative, Node-negative Breast Cancer With Intermediate 21-gene Signature Recurrence ScoresSemantic proximity Read

Favorable Locoregional Control in Clinically Node- Negative Hormone-receptor Positive Breast Cancer With Low 21-gene Recurrence Scores: a Single Institutional Study With 10-year Follow-upSemantic proximity Read

Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast CancerSemantic proximity Read

Adjuvant Chemotherapy Guidance for pT1-3N0-1 Breast Cancer Patients with HR+, HER2- subtype: a study based on SEER databaseSemantic proximity Read

Utilization and Outcomes of the 21-Gene Recurrence Score in pN2 Breast Cancer PatientsSemantic proximity Read

21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010-2013.Semantic proximity Read

Utilization and impact of 21-gene recurrence score assay for breast cancer in clinical practice across the United States: lessons learned from the 2010 to 2012 National Cancer Data Base analysis.Semantic proximity Read

Development and validation of a novel HER2RI assay for predicting the risk of recurrence and survival in HER2-positive early breast cancerSemantic proximity Read

Correlation Analysis of 21-Gene Recurrence Score with Gene Pathway Expression and Clinicopathological Features in Hormone Receptor-Positive Early-Stage Breast CancerSemantic proximity Read

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast CancerSemantic proximity Read

Risk factors, prognostic factors, and nomograms for distant metastasis in patients with triple-negative breast cancer: a population-based studySemantic proximity Read